Essai clinique NCT07063745 · Metastatic Non-small Cell Lung Cancer With MTAP Deletion

Essai clinique NCT07063745 (phase II/III) est «en recrutement» sur ClinicalTrials.gov.

Pathologie: Metastatic Non-small Cell Lung Cancer With MTAP Deletion · Interventions enregistrées: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel · Dates enregistrées (source): 2026-01-02, 2031-08-12, 2025-07-14, 2026-10-23.

Résumé de l’étude (source : ClinicalTrials.gov, texte original en anglais):

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

Source: https://clinicaltrials.gov/study/NCT07063745